There is a large body of evidence suggesting that more aggressive cancers are linked to the absence of nuclear PTEN in patients [16], [17], [21], [43], [44], [45] Thus, nuclear and cytoplasmic detection of PTEN using aptamers and antibodies could be an important indicator for clinical prediction. This evidence concerns the gene PTEN and cancer.